Alaunos Therapeutics Files 8-K, Confirms Nasdaq Listing

TL;DR

**Alaunos Therapeutics filed a routine 8-K, no major news.**

AI Summary

Alaunos Therapeutics, Inc. (TCRT) filed an 8-K on January 29, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates a routine update to their public record, confirming their status as a Delaware-incorporated company with Common Stock traded on the Nasdaq Capital Market under the symbol TCRT. For investors, this filing primarily serves as a confirmation of their current operational and listing details, without disclosing new material financial or strategic changes, meaning there's no immediate impact on stock valuation from this specific filing.

Why It Matters

This filing confirms Alaunos Therapeutics' current operational and listing details, providing transparency but no new material information that would immediately affect stock price.

Risk Assessment

Risk Level: low — This 8-K is a standard informational filing and does not introduce new risks or material changes to the company's operations or financial health.

Analyst Insight

A smart investor would note this as a routine filing confirming existing information, and would not make any immediate trading decisions based solely on this 8-K. Further research into the company's financial performance and strategic developments would be necessary.

Key Numbers

• $0.001 — par value per share (par value of Alaunos Therapeutics' Common Stock)

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — the registrant filing the 8-K
• TCRT (company) — trading symbol for Alaunos Therapeutics, Inc.
• Nasdaq Capital Market (company) — exchange where Alaunos Therapeutics' stock is registered
• Delaware (company) — state of incorporation for Alaunos Therapeutics, Inc.
• $0.001 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• Alaunos Therapeutics will continue to trade on the Nasdaq Capital Market under the symbol TCRT. (Alaunos Therapeutics, Inc.) — high confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TCRT Nasdaq Capital Market

Filing Documents

• e619210_8k-at.htm (8-K) — 25KB
• e619210_ex3-1.htm (EX-3.1) — 29KB
• 0001193805-24-000103.txt ( ) — 230KB
• tcrt-20240129.xsd (EX-101.SCH) — 3KB
• tcrt-20240129_lab.xml (EX-101.LAB) — 33KB
• tcrt-20240129_pre.xml (EX-101.PRE) — 22KB
• e619210_8k-at_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On January 29, 2024, the Board of Directors of Alaunos Therapeutics, Inc. (the "Company") approved the filing with the Secretary of State of the in order to effect a reverse stock split of the Company's common stock at a ratio of 1-for-15 (the "Reverse Split"). The Charter Amendment provides that the Reverse Split will become effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company's issued and outstanding common stock will automatically be combined and converted into 1 share of common stock. Beginning with the opening of trading on Thursday, February 1, 2024, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "TCRT," but will trade on a split-adjusted basis under a new CUSIP number, 98973P200. The Charter Amendment effecting the Reverse Split was approved by the stockholders of the Company at the Company's Annual Meeting of Stockholders held on June 6, 2023. In connection with approving the Reverse Split, the Company's stockholders granted authority to the Board of Directors of the Company (the "Board") to determine in its sole discretion the exact ratio within the range of 1-for-5 to 1-for-15 at which to effectuate the Reverse Split. The Reverse Split was initially approved by the Board on April 14, 2023 and the ratio of 1-for-15 was approved by the Board on January 12, 2024. Equiniti Trust Company ("Equiniti") is acting as the exchange agent for the Reverse Split. Equiniti will provide instructions to stockholders regarding the process for exchanging their pre-split shares for post-split shares. The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Charter Amendment, which is filed as Exhibit 3.1 to this Current R

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Second Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc. 104 Cover Page Interactive Data (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALAUNOS THERAPEUTICS, INC. By: /s/ Michael Wong Michael Wong Vice President, Finance Date: January 29, 2024

View Full Filing

View this 8-K filing on SEC EDGAR